Jerusalem-based Chiasma has raised $33.8 million of a proposed $56.3 million round, despite cancellation of an approximately $595 million deal with global biotech Roche last summer. New funds were provided by a portfolio of investors including MPM Capital, Abingworth, 7-Med Health Ventures LP, ARCH Venture Partners and F2 and F3 Ventures. Chiasma has shown promise as a ...

Rehovot-based NeuroDerm Ltd. (NASDAQ: NDRM) ended 2014 on a high note as it saw its share price more than double following announcement of positive results in a Phase IIa Parkinson’s drug trial. According to the company, administration of a continuous subcutaneous high-level dose of ...

Many physicians hesitate to prescribe medical marijuana for pain relief because of its variability in efficiency, largely due to current dosage techniques. Tel Aviv-based Syqe Medical is giving these doctors a new option: more fine-tuned control over their patients’ marijuana ...